Last reviewed · How we verify

BIVV009 — Competitive Intelligence Brief

BIVV009 (BIVV009) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TFPI inhibitor monoclonal antibody. Area: Hematology.

phase 3 TFPI inhibitor monoclonal antibody Tissue Factor Pathway Inhibitor (TFPI) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

BIVV009 (BIVV009) — Bioverativ, a Sanofi company. BIVV009 is a monoclonal antibody that inhibits tissue factor pathway inhibitor (TFPI) to enhance thrombin generation and restore hemostasis in hemophilia patients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BIVV009 TARGET BIVV009 Bioverativ, a Sanofi company phase 3 TFPI inhibitor monoclonal antibody Tissue Factor Pathway Inhibitor (TFPI)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TFPI inhibitor monoclonal antibody class)

  1. Bioverativ, a Sanofi company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BIVV009 — Competitive Intelligence Brief. https://druglandscape.com/ci/bivv009. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: